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Major Depression with Ischemic Heart Disease: Effects
of Paroxetine and Nortriptyline on Long-Term Heart
Rate Variability Measures
Vikram K. Yeragani, Vanessa Pesce, Anusha Jayaraman, and Steven Roose
Background: Studies have linked depression to sudden
death and serious cardiovascular events in patients with
preexisting cardiac illness. Recent studies have shown
decreased vagal function in cardiac patients with depres-
sion and depressed patients without cardiac illness.
Methods: We compared 20-hour, sleeping, and awake
heart period variability measures using spectral analysis,
fractal dimension, and symbolic dynamics in two patient
groups with major depression and ischemic heart disease
(mean age 59–60 years) before and after 6 weeks of
paroxetine or nortriptyline treatment.
Results: Spectral measures showed decreases in awake
and sleeping total power (TP: 0.0–0.5 Hz), ultra low
frequency power (ULF: 0–0.0033 Hz), very low frequency
power (VLF: 0.0033–0.04 Hz), and low-frequency power
(LF: 0.04–0.15 Hz) for nortriptyline condition and a
decrease in high-frequency power (HF: 0.15–0.5 Hz) for
the awake condition in patients who received nortriptyline.
A measure of nonlinear complexity, WC-100, significantly
increased after paroxetine during the awake condition.
Conclusions: These findings suggest that nortriptyline has
stronger vagolytic effects on cardiac autonomic function
compared with paroxetine, which is in agreement with
previous clinical and preclinical reports. Paroxetine may
have some cardio-protective effects, especially in cardiac
patients. Biol Psychiatry 2002;52:418–429 © 2002
Society of Biological Psychiatry
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Introduction
Recently major depression has been linked to poorprognosis in patients with heart disease (Carney et al
1993, 1995, 1997; Dalack and Roose 1990; Everson 1998;
Frasure-Smith et al 1993; Horrobin and Bennett 1999;
Musselman 1998), and some studies have shown de-
creased heart rate variability (HRV) in these vulnerable
patients with and without overt cardiac disease (Krittiya-
phong et al 1997; Stein et al 2000; Yeragani 2000). One
study suggested that negative feelings were associated
with arterial wall thickening (Agewall 1996).
Roose et al (1998, 1999) have reported that nortriptyline
was associated with a higher rate of side effects compared
with paroxetine in depressed patients with heart disease.
Although it is not directly relevant, several articles have
dealt with the issue of sudden cardiac death in children
who were placed on tricyclics such as desipramine and the
effects of these agents on cardiac autonomic function
(Biederman et al 1993; Mezzacappa et al 1998; Walsh et
al 1994; Werry et al 1995). Together these findings
underscore the importance of choosing an antidepressant
that has a favorable cardiac side-effect profile. Some of the
recent noninvasive techniques such as HRV and QT
interval variability are valuable tools to study the effect of
various antidepressants in patients with major depression.
An increase in cardiac sympathetic function or a decrease
in vagal function can lead to serious ventricular arrhyth-
mias and sudden death (Rozanski et al 1988). Recent
noninvasive techniques on heart rate (HR) and QT interval
variability show a great deal of promise to study cardiac
autonomic function in different disorders and also to
evaluate the effects of various drugs (Atiga et al 1998;
Berger et al 1997; Malik and Camm 1990; Malliani et al
1991; Yeragani 1995; Yeragani et al 1993a, 2000b,
2000c). Although Yeragani et al (1991) did not find
significant differences in time domain measures of 5-min
segments of heart rate between control subjects and
patients with major depression, their findings on 24-hour
HRV and measures of nonlinearity and chaos suggest that
these patients appear to have a relative decrease in cardiac
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vagal function (Yeragani et al 2002a). In fact, in a recent
report, Yeragani et al have shown highly significant
differences in largest Lyapunov exponent (LLE), a mea-
sure related to cardiac vagal function in patients with panic
disorder (Radhakrishna and Yeragani, in press). They also
showed that word count (WC-100), a measure derived
from symbolic dynamics, was significantly lower in these
patients with anxiety, which also relates to nonlinear
complexity of the time series (Yergani et al 2000a). This
is important in view of the strong association between
decreased HRV and significant cardiovascular mortality in
patients with cardiac disease, depression, anxiety and also
in normal control subjects (Bigger et al 1992; Kawachi et
al 1994; Kleiger et al 1987; Molgaard et al 1991).
Spectral analysis of long-term HR or heart period (HP)
time series can be used to obtain powers in frequency
bands such as ultra low frequency power (ULF: 0–0.0033
Hz), very low frequency power (VLF: 0.0033–0.04 Hz),
low-frequency power (LF: 0.04–0.15 Hz), and high-
frequency power (HF: 0.15–0.5 Hz). High-frequency
power is related to respiratory sinus arrhythmia, thus
reflecting cardiac vagal function, whereas LF power is
mediated dually by vagal and sympathetic systems (Ak-
selrod et al 1981; Lindqvist et al 1990; Pomeranz et al
1985). Although controversial, some investigators have
used the LF/HF ratios as indicative of sympathovagal
interaction (Cacioppo et al 1994; Pagani 1986). The
mechanism is not clearly understood, but ULF and VLF
may also be mediated by sympathetic, rennin-angiotensin,
and thermoregulatory mechanisms (Bonaduce et al 1994;
Lindqvist et al 1990; Niemela et al 1994).
Previous studies suggest that tricyclic antidepressants
(TCAs) result in tachycardia, prolongation of QTc inter-
val, decreased HRV, and an increase in QT variability
(Georgatas et al 1987; Glassman and Bigger 1981; Glass-
man et al 1987; Roose and Glassman 1989; McLeod et al
1992; Yeragani et al 1992, 2000c), which are all associ-
ated with significant cardiovascular events. Rechlin (1994)
showed that amitriptyline significantly decreases HRV in
patients with depression. On the other hand, Tucker et al
(1997) reported that paroxetine increased cardiac vagal
activity in patients with panic disorder; however, our
previous findings on paroxetine in patients with panic
disorder in their 30s have shown a decrease of cardiac
vagal function as suggested by a decrease of high-fre-
quency power of HR (Yeragani et al 1999).
Several investigators have demonstrated the nonlinear
nature of the HR or HP time series and have also shown
the additional utility of these measures to the traditionally
used time and frequency domain measures (Braun et al
1998; Curione et al 1998; Ganz et al 1993; Glenny et al
1991; Goldberger and West 1987; Guzzetti et al 1996; Ho
et al 1997; Kaplan et al 1991; Lipsitz and Goldberger
1992; Lombardi et al 1996; Pincus et al 1991;
Radhakrishna et al 2000; Radhakrishna and Yeragani,
2001; West and Goldberger 1987; Yeragani et al, 2002a,
2002b). Although there are numerous techniques to quan-
tify nonlinearity, complexity, predictability, and chaos,
these techniques need further evaluation as to what exactly
they represent in terms of physiologic significance and
their relationship to a particular cardiac condition. Poon
and Merrill (1997) reported a decrease of cardiac chaos in
severe congestive heart failure, a condition associated with
sudden death. Voss et al (1996, 1998) showed that
nonlinear measures seem to be a better predictor of high
arrhythmia risk than just the global heart rate variability
using multiparametric analysis. Makikallio et al (1999)
showed that fractal analysis of HR could be used as a
predictor of mortality in patients with depressed left
ventricular function after acute myocardial infarction
(MI). Huikiuri et al (1999, 2001) discussed the time,
frequency domain, and the nonlinear measures in their
reports and suggested that the nonlinear measures of HR
variability are promising tools to stratify risk and as
predictors of death and life-threatening arrhythmias in
postinfarction populations. Thus, mounting evidence sug-
gests that the nonlinear measures are clinically important.
It is important to understand the effects of various
antidepressant drugs on cardiac autonomic function in
various age groups of patients using these novel noninva-
sive techniques. In this study, we sought to investigate the
effects of paroxetine and nortriptyline in patients with
major depression and ischemic heart disease aged about 60
years using HPV and Holter electrocardiograph (ECG)
records obtained in a previous treatment study (Roose et al
1998). In this study, Roose et al found that 61% of patients
on paroxetine and 55% on nortriptyline improved after
treatment. There was no significant change in blood
pressure or conduction intervals on ECG with either drug.
Paroxetine had no sustained effects on heart rate or
rhythm; however, nortriptyline produced a significant
increase in HR and a decrease in standard deviation (SD)
of all normal R–R intervals. Nortriptyline produced ad-
verse cardiac events in 18% of patients compared with
only 2% of patients in the paroxetine group.
We used frequency domain measures and also measures
of symbolic dynamics (Voss et al 1996; Yeragani et al
2000a), which reflects the nonlinear complexity of these
time series and one method of computing fractal dimen-
sion (FD) (Katz 1988; Yeragani et al 1993b, 1997, 1998b).
We hypothesized that nortriptyline treatment would be
associated with a more significant decrease in various
measures of HRV compared with paroxetine based on the
previous finding of a significant vagolytic effect of nor-
triptyline in these patients (Roose et al 1998).
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Methods and Materials
Subjects
ORIGINAL STUDY DESIGN. This study was conducted in
four University research centers (Roose et al 1998) and was
approved by the internal review boards at all four sites for the
protection of subjects. The inclusion criteria were DSM-IV
criteria for major depressive disorder, unipolar subtype, with a
score of 16 or higher on the 17-item Hamilton Rating Scale for
Depression (HAMD; Hamilton 1960), ischemic heart disease,
and the patient’s being capable and willing to sign informed
consent to participate in this study aimed at the cardiovascular
safety of antidepressant medication. Patients were considered to
have ischemic heart disease if they had had an MI, coronary
artery bypass graft surgery, or coronary angioplasty; had a
positive stress test; or had angiographic evidence of a 75% or
greater luminal narrowing of a major coronary artery or one of its
primary branches. Patients were excluded if the MI occurred
within 3 months before their recruitment, a baseline QTc of 460
msec or more, unstable or crescendo angina, or if they were
receiving drugs with class I antiarrhythmic activity or warfarin.
After patients signed the informed consent, baseline cardiac
testing was conducted during a 2-week placebo period, including a
24-hour continuous Holter ECG record and a routine 12-lead ECG
at the beginning and end of the placebo period. At the end of the
placebo period, if the patient had completed with the study proce-
dures and continued to meet inclusion and exclusion criteria, he or
she was randomized by permuted blocks of 10 to treatment with
either paroxetine or nortriptyline for a double-blind 6-week trial.
DOSING. Patients aged less than 65 years received an initial
dose of 20 mg/day of paroxetine for the first 3 weeks; older
patients were started at 10 mg/day for the first week, and then the
medication was increased to 20 mg/day for the next 2 weeks. At
the end of 3 weeks, if patients did not show a 50% decrease in
HAMD scores, the paroxetine dose was increased to 30 mg and,
if necessary, to 40 mg at the end of week 5. The nortriptyline
dose was started at 25 mg and increased to 50 mg by day 3. On
the seventh day, plasma level was measured and the dose
adjusted to achieve a plasma nortriptyline level between 304 and
456 nmol/L. The idea was to have the dose within the therapeutic
range of 190–570 nmol/L (50–150 ng/mL). Medication compli-
ance was monitored by weekly pill counts and plasma level
measurements; blood samples were taken from patients on
paroxetine as well.
DRUG DISCONTINUATION. Medications were discontinued
if there was an adverse cardiac event, if there was a greater than
50% increase in the QRS interval from baseline, if the QRS
interval exceeded 180 msec in patients with bundle-branch block
at baseline, if the QTc interval exceeded 500 msec, or if a patient
developed a proarrhythmic effect. Additional factors that were
taken into account included cardiac enzyme levels, 24-hour
ECG, and significant blood pressure changes.
CARDIAC ASSESSMENT. We obtained 24-hour ECG before
and after 2 weeks of placebo administration. Patients received
active medication for 6 weeks. We then repeated 24-hour ECGs
at the end of 2 and 6 weeks of medication treatment. Complete
data included four 24-hour ECG records.
The mean  SD for paroxetine dose was 22  5 mg/day and
74  30 mg/day for nortriptyline. At week 6, the nortriptyline
levels were within the therapeutic range. In the original sample,
37/41 (90%) of patients treated with paroxetine completed the
trial, and 25 (68%) were responders. Sixty-five percent (26/40)
completed the nortriptyline trial, and 22 (85%) were responders.
Twenty-Four Hour Heart Rate Variability
The techniques used for this study were similar to those used in
our previous studies (Yeragani et al 1997, 1998a). This study
included only those patients who had at least 20,000 sec of data
during the awake period, pretreatment records from before
placebo administration, and records from 6 weeks after treat-
ment. Many patients did not have all these records, so we had to
limit our analyses to two records; however, we compared pre-
and postplacebo lead-in records and found no significant differ-
ence in any of our HRV measures. The reason to exclude the
2-week posttreatment record was that the effects of the drugs
might not have been observable by then. Twenty-four patients
were included in the paroxetine treatment study and 20 patients
in nortriptyline study. We have used means and standard devia-
tions throughout the text and tables of this article. Thirty-three
patients had 20-hour data, 44 had awake data, and 30 had
sleeping data. Age ranges of the paroxetine group for the
20-hour, awake, and sleeping data sets, respectively, were 60.4
10.5, 58.0  10.2, and 60.4  10.5 years; for the nortriptyline
group, they were 60.8  13.4, 61.0  13.2, and 61.6  13.1
years.
Twenty-four hour ECG was recorded using cassette tapes and
digitized with a Marquette 8000 scanner; QRS labeling and
editing was done using standard Marquette algorithms. The
ASCII files of R–R intervals in milliseconds were edited accord-
ing to previous techniques that have been described in detail
(Huikuri et al 1994; Yeragani et al 1997, 1998). These data were
edited using software that eliminated any premature ventricular
beats. This method is similar to that used by Huikuri et al (1994).
An R–R interval was interpreted as a premature beat if it deviated
from previous qualified interval by more than a tolerance level of
30%. These data were eliminated and the resulting gaps filled
with an average value in the immediate neighborhood. The edited
time series were then sampled at 2 Hz using the technique
described by Berger and coworkers to obtain the instantaneous
HR (Berger et al 1986). This stepwise continuous instantaneous
HR signal maintains an amplitude equal to the reciprocal of the
R–R interval and the convolution of the HR signal with the
rectangular window has the effect on the power spectrum of
multiplication by a low-pass filter. A 2-Hz sampling rate would
allow an accurate estimation of the power spectrum up to 0.5 Hz,
which is equivalent to a breathing rate of 30/min. From here
forward, all data were converted to a R–R interval time series
(60000/HR in beats per minute [bpm]). Then the data were
detrended using a linear detrending technique before the other
analyses except for the nonlinear analyses of FD and symbolic
dynamics.
SPECTRAL ANALYSIS. The power spectrum was obtained as
the magnitude squared of the Fourier transform using a rectan-
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gular data window. The powers were integrated in the following
bands; total power (TP): 0–0.5 Hz, ULF: 0–0.0033 Hz, VLF:
0.0033–0.04 Hz, LF: 0.04–0.15 Hz, and HF: 0.15–0.5 Hz.
Relative powers were calculated as the percentages of total
power in each frequency band. We include a detailed description
of the methods used to calculate fractal dimension and measures
of symbolic dynamics in the Appendix.
FRACTAL DIMENSION. We calculated FD according to the
same method used in our previous studies (Yeragani et al 1993b,
1997, 1998b), which was originally described by Katz (1988).
(See Appendix 1).
SYMBOLIC DYNAMICS. These techniques have been de-
scribed in detail by Kurths et al (1995) and Voss et al (1996) and
recently used in our study in patients with panic disorder
(Yeragani et al 2000b). (See Appendix 1). We have also
calculated the SD of the word sequence (WSDVAR-100) after
transformation of the sequence by using the words 1 or 3, as
suggested by Voss et al (1996). In another analysis, we obtained
the symbol sequences using only 0 or 1, where 0 represents the
difference between consecutive beats lower than 5, or 100 msec,
and 1 represents the cases in which the difference between two
successive beats exceeded this limit. We then calculated all
three-digit words that contained either 000 (A) or 111 (B). We
call these PN-5-A, PN-100-A and PN-5-B, and PN-100-B.
Statistical Analysis
We initially performed a three-way analysis of variance
(ANOVA) with the two drug conditions as the grouping factor
and the awake and sleeping periods as one repeated measure, and
pre- and postdrug (first and fourth Holter sessions) values as the
second repeated measure. Because there were significant differ-
ences between sleeping and awake periods, we chose to perform
two-way ANOVAs separately for awake and sleeping periods.
We used two-way ANOVA for repeated measures with the drug
condition as the grouping factor and pre- and posttreatment (6
weeks) measures as the repeated measures. Significant effects
were followed up by paired t tests to compare patients separately
for each drug condition. All tests were two-tailed, and a proba-
bility value of .025 was considered significant because we
performed two post hoc tests. Pearson’s product–moment corre-
lations were used to examine the relationship between HP
variability measures of interest and treatment effects. For those
subjects that had data before and after placebo treatment, the HP
variability measures were compared using ANOVAs for repeated
measures.
Results
Age was very similar between paroxetine and nortriptyline
groups. There were no significant group differences be-
tween baseline and after-placebo lead-in periods for any of
the HP variables. In fact, some of the values were almost
identical. Tables 1 and 2 show the results of spectral
analysis and measures of symbolic dynamics. Tables 3 and
4 show the results of two-way ANOVAs for the same
measures.
For the two-way ANOVAs, drug effect refers to parox-
etine versus nortriptyline and treatment effect for pre-
versus posttreatment conditions. There were significant
interaction and treatment effects for the mean 20-hour HP,
significant interaction effect for the awake mean HP, and
an interaction effect for the sleep mean HP (Tables 1 and
3; Figure 1). This was due to a significant decrease of R–R
interval after nortriptyline treatment.
Spectral Measures
Tables 1 and 3 show the results of the spectral analyses.
Two-way ANOVA of the 20-hour data showed no signif-
icant differences for TP, ULF, VLF, LF, or HF; however,
there was a treatment effect for the LF/HF ratios, showing
a significant decrease for both treatment conditions. There
was also a significant increase of relative HF power during
either condition as showed by the treatment effect (parox-
etine: 2.1  4.2 vs. 2.7  4.6; nortriptyline: 1.3  4.6 vs.
2.1  2.0).
For the awake condition, there were significant interac-
tion and treatment effects for TP, due to the decrease of TP
during nortriptyline condition (Figure 2). For VLF, there
were significant interaction and treatment effects suggest-
ing a significant decrease during nortriptyline treatment
(Figure 2). For LF, there also were significant interaction
effects suggesting a significant decrease during nortripty-
line treatment (Figure 2). For HF power, there was only a
decrease during nortriptyline condition. There was a sig-
nificant treatment effect for the LF/HF ratios suggesting a
decrease during both treatments. There was also a signif-
icant increase of relative HF power during both treatments
(paroxetine: 3.1  4.8 vs. 4.1  5.8; nortriptyline: 2.1 
1.4 vs 3.2  2.8).
For the sleeping condition, there were significant inter-
action and treatment effects for TP, due to the decrease of
TP during nortriptyline condition. For ULF, there was a
significant treatment effect suggesting a decrease during
either treatment condition; however, post hoc tests showed
a significant decrease of ULF only for the nortriptyline
condition. For VLF, there were significant interaction and
treatment effects suggesting a significant decrease during
nortriptyline treatment. For LF, there also were significant
interaction and treatment effects suggesting a significant
decrease during nortriptyline treatment.
Symbolic Dynamics
Tables 2 and 4 show the results of analysis using symbolic
dynamics measures. Analysis of the 20-hour data revealed
significant interaction effects for PN-5-A and PN-5-B
suggesting an increase of the former measure and a
Antidepressants and Ischemic Heart Disease 421BIOL PSYCHIATRY
2002;52:418–429
decrease of the latter during nortriptyline condition. For
the awake condition, there was a significant interaction
effect for word count (WC-100) during paroxetine condi-
tion as suggested by a significant interaction effect (Figure
3). There were significant interaction effects for PN-5-A
and PN-5-B suggesting an increase of the former measure
and a decrease of the later during nortriptyline condition.
There was also a significant interaction effect for PN-
100-A suggesting an increase of this measure only during
nortriptyline condition (Figure 2).
For the sleeping condition, there was a significant
interaction effect for PN-5-B suggesting a decrease during
nortriptyline condition.
Fractal Dimension
There were no significant differences in FD for any of the
periods for pre- and postdrug conditions (paroxetine: 20
hours: 1.23  .07 vs. 1.23  .07; awake: 1.24  .07 vs.
1.26  .08; sleeping: 1.29  .10 versus 1.28  .09;
nortriptyline: 20 hours: 1.22  .04 vs. 1.20  .05; awake:
1.22  .05 versus 1.22  .05; sleeping: 1.27  .06 versus
1.25  .07).
Discussion
Spectral Analysis
The results clearly show that in these patients with
depression and ischemic heart disease (mean age  60
years), nortriptyline significantly decreases TP, ULF,
VLF, and LF powers during awake and sleeping periods.
Surprisingly, the effect of nortriptyline on HF power is not
highly pronounced except during the awake state, and
paroxetine did not result in any decrease in spectral
powers. This is in contrast to the reports of Yeragani et al
on paroxetine’s effect on HF power in patients with panic
disorder (Yeragani et al 1999); however, that study in-
cluded patients with panic disorder without cardiac dis-
ease, and the mean age group of the patients was about 38
years. One other important finding in this study was the
Table 1. Spectral Variables of Heart Period before and after Treatment
Paroxetine Nortriptyline
Predrug Postdrug Predrug Postdrug
20 Hour
Mean HP 865.23  109.23 868.67  123.80 843.50  166.42 736.22  132.41c
HP SD 119.08  42.23 107.85  32.12 122.86  74.09 97.29  29.94
TP 8.96  .85 8.78  .64 8.95  1.04 8.39  .79
ULF 8.90  1.27 8.55  .71 8.78  1.10 8.25  .79
VLF 6.70  .64 6.62  .58 6.49  .68 5.87  .88
LF 5.38  .79 5.33  .63 5.23  .68 4.65  1.00
HF 4.45  1.13 4.59  .94 4.36  .86 4.10  1.08
LF/HF ratio 3.57  3.22 2.43  1.30 3.03  2.25 2.50  2.33a
Awake
Mean HP 816.49  125.43 836.99  108.53 800.61  121.63 749.39  109.83a
HP SD 80.48  31.96 77.41  18.68 89.31  49.40 63.87  23.68
TP 7.94  .76 7.95  .48 8.02  .91 7.51  .66b
ULF 7.59  .90 7.59  .53 7.73  1.01 7.26  .71
VLF 5.99  .61 6.17  .60 5.95  .67 5.24  .89c
LF 4.91  .87 5.02  .68 4.89  .77 4.22  1.13c
HF 3.99  .97 4.24  1.01 3.98  .89 3.73  1.02
LF/HF ratio 3.63  3.59 2.70  1.53 3.20  2.35 2.25  1.94c
Sleeping
Mean HP 950.52  103.76 973.63  148.86 949.93  209.11 850.75  135.08a
HP SD 85.46  28.72 77.51  20.87 85.71  32.53 59.69  23.18
TP 8.08  .71 7.94  .56 8.09  .71 7.36  .70c
ULF 7.55  .82 7.29  .63 7.52  .81 6.87  .75a
VLF 6.60  .76 6.68  .65 6.64  .66 5.70  .97c
LF 5.40  .96 5.45  .73 5.64  .81 4.55  1.10b
HF 4.54  1.29 4.56  1.05 4.60  1.08 4.03  1.17
LF/HF ratio 3.02  2.29 3.12  2.82 3.79  3.14 2.51  2.31
Total power (TP): 0–.5 Hz; ultra low frequency power (ULF): 0–.0033 Hz; very low frequency power (VLF): .0033–.04 Hz; low-frequency power (LF): .04–.15 Hz;
high-frequency power (HF): .15–.5 Hz. The units for power are in Ln of milliseconds squared. HP, heart period. Significance indicates change from predrug condition in
a paired t test (two-tailed).
ap  .05.
bp  .01.
cp  .005.
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decrease of sleep ULF power with nortriptyline, which is
especially important in light of the report of Bigger et al
(1992) linking the decrease in ULF power to significantly
increased mortality in cardiac patients. There was a
significant decrease of LF/HF ratios during both treat-
ments, but it was more pronounced during the nortriptyline
condition, which may in fact be a beneficial effect. The
concept of LF/HF ratio as a relevant measure of sympa-
thovagal balance is controversial, however (Cacioppo et al
1994; Pagani et al 1986) and this finding should also be
viewed in the total context of a decrease in HP variability
in various frequency bands. As expected, there was a
significant decrease of mean HP during nortriptyline
treatment. The increase in relative HF power during either
Table 2. Symbolic Dynamic Measures of Heart Period before and after Treatment
Paroxetine Nortriptyline
Predrug Postdrug Predrug Postdrug
20 Hour
WSDVAR 1.99  .45 1.89  .41 2.02  .32 1.82  .33
Word Count 36.82  6.38 38.88  5.66 37.75  5.18 37.63  6.39
PN-5-A 52.72  10.58 50.46  10.56 53.19  7.44 58.49  10.98a
PN-5-B 5.95  2.74 6.20  2.68 5.25  2.22 3.92  3.17a
PN-100-A 98.91  2.93 99.04  2.75 99.56  .95 99.73  .45
PN-100-B .004  .02 .032  .03 .002  .008 .0000  .0000
Awake
WSDVAR 1.62  .51 1.59  .44 1.65  .48 1.39  .40
Word Count 32.21  6.09 35.00  6.00b 33.70  6.02 33.2  5.86
PN-5-A 53.57  12.49 50.26  12.15 54.48  9.83 59.26  11.08
PN-5-B 4.68  3.23 5.32  2.92 3.98  2.10 3.24  3.08
PN-100-A 99.50  1.70 99.42  1.60 99.72  .57 99.83  .38
PN-100-B .0004  .002 .0008  .003 .0005  .002 .0000  .0003
Sleeping
WSDVAR 1.39  .36 1.26  .43 1.27  .36 1.13  .59
Word Count 30.88  7.27 30.82  6.94 31.00  4.61 29.07  6.81
PN-5-A 49.54  10.22 50.24  9.81 49.34  8.64 55.03  10.89
PN-5-B 6.81  3.77 7.64  4.17 7.90  2.69 4.74  3.13a
PN-100-A 98.45  4.23 98.71  4.26 99.26  1.81 99.75  .55
PN-100-B .009  .04 .008  .03 .007  .03 .0000  .0000
WSDVAR, standard deviation of the word sequence; PN, percentage of three digit words (000 or 111) for a given period (5 to 100 milliseconds). Significance indicates
change from predrug condition in a paired t test (two-tailed).
ap  .05.
bp  .005.
Table 3. Results of Two-Way Analysis of Variance for Spectral Variables of Heart Period before and after Treatment
Group effect Treatment effect Interaction effect
20 Hour
Mean HP ns F  6.3; df  1,31; p  .02 F  7.6; df  1,31; p  .009
LF/HF Ratio ns F  5.7; df  1,31; p  .02 ns
Awake
Mean HP ns ns F  5.6; df  1,42; p  .02
TP ns F  5; df  1,42; p  .03 F  5.2; df  1,42; p  .03
VLF ns F  8.3; df  1,42; p  .006 F  22.8; df  1,42; p  .00001
LF ns F  6.2; df  1,42; p  .05 F  12.4; df  1,42; p  .001
HF ns ns F  4.0; df  1,42; p  .05
LF/HF Ratio ns F  7.0; df  1,42; p  .008 ns
Sleep
Mean HP ns ns F  7.9; df  1,28; p  .009
TP ns F  13.7; df  1,28; p  .0009 F  6.1; df  1,28; p  .02
ULF ns F  6.0; df  1,28; p  .02 ns
VLF ns F  13.8; df  1,28; p  .0009 F  18.9; df  1,28; p  .0001
LF ns F  13.6; df  1,28; p  .001 F  16.3; df  1,28; p  .0004
Total power (TP): 0–.5 Hz; ultra low frequency power (ULF): 0–.0033 Hz, very low frequency power (VLF): .0033–.04 Hz, low-frequency power (LF): .04–.15 Hz,
high-frequency power (HF): .15–.5 Hz. The units for power are in Ln of milliseconds squared. HP, heart period.
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treatment condition is most likely due to a more significant
decrease in total power compared with HF power. This
again underscores the importance of using absolute as well
as relative powers. It also explains, in part, the significant
decrease of LF/HF ratios during both drug conditions.
Paroxetine and Antimuscarinic Effects
A brief review of the literature suggests that, compared
with tricyclics, paroxetine has weak affinity for muscarinic
receptors (e.g., 15-fold weaker than amitriptyline; Johnson
1989; Thomas et al 1987). Hiemke (1994) stated that the
low affinity of paroxetine to muscarinic receptors is not
relevant for therapeutic effects because paroxetine is 2 to
23 times more potent for the reuptake inhibition of
serotonin than other SSRIs. Hunter and Wilson (1995)
reported that tricyclics produced a significant reduction in
salivary flow, presumably due to muscarinic receptor
blockade. Fluoxetine and paroxetine did not produce any
significant change in this variable. Pollock et al (1998)
also reported that at therapeutic plasma concentrations,
paroxetine is associated with approximately one fifth the
anticholinergic potential of nortriptyline in older patients.
Bitsios et al (1999) studied the effects of venlafaxine,
paroxetine, and desipramine on the pupillary light reflex in
Figure 3. The 20,000-sec awake word count (WC-100) for a
patient after nortriptyline treatment and another after paroxetine
treatment condition, illustrating increased word count after par-
oxetine treatment.
Figure 2. Interaction effects (analysis of variance) for the par-
oxetine and nortriptyline conditions. Significant differences are
for pre- versus postdrug. TP, total power; VLF, very low
frequency; LF, low frequency; WC, word count; PN, percentage
of three digit words (000 or 111) for a given period (5 to 100
milliseconds); Par, paroxetine; Nt, nortriptyline.
Table 4. Results of Two-Way Analysis of Variance for
Measures of Symbolic Dynamics of Heart Period before and
after Treatment
Group
effect
Treatment
effect Interaction effect
20 Hour ns ns
PN-5-A ns ns F  6.2; df  1,13; p  .02
PN-5-B ns ns F  4.4; df  1,31; p  .04
Awake
WC-100 ns ns F  5.0; df  1,42; p  .03
PN-5-A ns ns F  6.2; df  1,42; p  .03
PN-5-B ns ns F  4.3; df  1,42; p  .04
PN-100-A ns ns F  4; df  1,42; p  .05
Sleeping
PN-5-B ns ns F  9.3; df  1,28; p  .005
PN, percentage of three digit words (000 or 111) for a given period (5 to 100
milliseconds); WC, word count.
Figure 1. The 24-hour heart period time series for one patient in
each drug condition. RR, interbeat interval in milliseconds.
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humans and found no significant changes with paroxetine,
whereas venlafaxine was associated with significant in-
crease in resting pupil diameter and a decrease in ampli-
tude. They concluded that this is consistent with blockage
of noradrenaline uptake. Owens et al’s study (Owens et al
1997) also suggests that paroxetine does not have signif-
icant affinity for Muscatine receptors. These studies sup-
port a lack of significant antimuscarinic effects of parox-
etine.
For spectral analysis, the results of awake and sleeping
periods showed highly significant differences compared
with the 20-hour period, most likely attributable to an
increased variance of each measure when longer data
segments, especially the combination of awake and sleep-
ing periods, were used.
Symbolic Dynamics
There was a significant increase in PN-5-A during the
20-hour and awake periods and a decrease of PN-5-B
during 20-hour as well as awake and sleeping periods after
nortriptyline due to a decreased complexity of the time
series. This means that many consecutive differences in
R–R intervals after nortriptyline that occur in a row are 
5 msec. This is because PN-5-A indicates the occurrence
of  5 msec consecutive differences in the R–R interval
time series, whereas PN-5-B indicates the occurrence of 
5-msec consecutive differences in the R–R intervals. It is
interesting to note that word count significantly increased
after paroxetine administration during the awake period.
This is important in connection with our previous findings
of decreased number of words in patients with panic
disorder, which suggests a decreased nonlinear complexity
of the time series (Yeragani et al 2000a). Similar findings
were also reported in patients with cardiac disease (Voss et
al 1996).
Fractal Dimension
Fractal dimension calculated by the technique described
by Katz (1988) correlates highly significantly with the HF
power of HR or HP time series and also the APEN values
calculated using the technique of Pincus et al (Pincus et al
(1991) (Yeragami et al 1993b, 1997, 1998b). Thus, it is
not surprising that there were no consistent and significant
changes in this measure in our study because the signifi-
cant findings were mostly limited to ULF, VLF, and LF
bands for the nortriptyline condition.
As we described in our previous reports (Radhakrishna
and Yeragani, 2001; Yeragani et al 2000a), we did not find
robust correlations between some of the nonlinear mea-
sures, such as WC-100 and LLE, and the spectral mea-
sures. Also, these measures discriminated normal control
subjects from patients with panic disorder more effectively
and also appear to be useful additions to measures of time
and frequency domain.
Cardiac Autonomic Function and Cardiovascular
Mortality
Cole et al (1999) recently showed that exercise recovery
time is prolonged in people who are prone to significant
cardiovascular events, which again relates impaired car-
diac vagal function to an increased risk for cardiovascular
mortality. Carney et al (2000) showed an improvement in
the parameters of HRV in depressed patients with myo-
cardial infarction who underwent cognitive psychother-
apy. Thus, the effectiveness of various treatment ap-
proaches should be evaluated in the context of
cardiovascular effects and probably using some of the
newer nonlinear measures such as the ones used in this
study. Other measures, including measures of chaos, may
prove effective in identifying other subtle changes in
autonomic function. Pool (1989) suggested that the con-
dition of health is in fact associated with a higher degree
of chaos.
Conclusions
The findings of this study suggest a more profound
vagolytic function of nortriptyline in patients with major
depression and cardiac disease. Thus, paroxetine may be a
safer choice in patients with myocardial infarction, per-
haps because of its weaker antimuscarinic effects. Each
case should be treated on its own merit, and, when
possible, some of the noninvasive measures described here
should be obtained before and after treatment.
Limitations of our study include the fact that we had to
exclude people in the placebo group (after placebo lead
in), leaving us with fewer subjects for comparison; how-
ever, the values of various HRV measures were similar,
and there were no significant differences between these
two pre- and postplacebo periods. The measures of sym-
bolic dynamics are relatively new, and future studies are
needed to understand the exact nature and utility of these
measures.
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Appendix 1. Calculation of Fractal Dimension
and Symbolic Dynamic Measures
Fractal Dimension (FD) was calculated according to the
same method used in our previous studies (Yeragami et al
1993b, 1997), which was originally described by Katz
(1988):
D log (L/a)/log[(K/a)/A],
where D is the fractal dimension, L is the total length of
the curve, a the average step length (a  L/n, where n is
the total number of steps), K  2/, and A is the area of
the circle potentially filled by an ideal random walk. The
following can be obtained after removing the constant K
from the formula:
D  log(n)/log(nd/L)  log(n)/[log(n) 
log(d/ L)]
where L is the sum of distances between successive points,
d is the planar extent of the curve that is the farthest
distance between starting point and the ith point of the
time series, and n is the number of steps in the curve.
Thus, the FD of a planar curve is defined as
FD  log (L)/log(d),
where L is the total length of the curve and d is the
diameter or planar extent of the curve. As suggested by
Katz (1998), we adopted the formula
FD  logL/a/logd/a  logn/	logn
 logd/L
 ,
where n is the total number of steps in the curve (total
number of points  1) and a is the average distance
between successive points. We used the same method
suggested by Katz (1988) using a custom-developed soft-
ware program. We calculated FDs for the 20-hour data and
also the awake and sleeping periods (20,000 sec each).
Symbolic Dynamics
These techniques have been described in detail by Kurths
et al (1995) and Voss et al (1996) and were recently used
in our study of patients with panic disorder (Yeragani et al
2000a). These techniques use a coarse-graining technique,
and the time series of the HP are transformed into symbol
sequences, such as 000, 011, 022, 033 . . . up to 333 by
using 0, 1, 2, and 3 as the symbols. For these four symbols,
there are 64 three-symbol sequences or “words,” which are
basically three-digit sequences. The transformation is done
using the mean R–R interval as  and a as a special
parameter, which is set to 0.05 to 0.1. Voss et al (1996)
reported that any value between 0.05 and 0.1 would give
reliable results for the R–R interval time series. In our
previous study, we called these parameters for total word
count WC-50 and WC-100 (to indicate the value of a as
0.05 or 0.1, respectively) and found that the values were
highly correlated. In this study, we present only WC-100
values for the word count.
The transformation for 0, 1, 2, and 3 is done in the
following way:
 tn tn 1 1 a  (0)
1  a    tn tn 1   (1)
1  a    tn tn 1   (2)
0  tn tn 1  1  a   (3)
Here  tn  tn  1 indicates the R–R interval, , the
mean of the R–R interval and a the parameter set at 0.1.
Thus, for each R–R interval, one symbol is assigned, and
for n number of intervals, n  1 words (three-digit
symbols) are obtained.
We have also calculated the SD of the word sequence
(WSDVAR-100) after transformation of the sequence
by using the words 1 or 3 as suggested by Voss et al
(1996). In another analysis, we obtained the symbol
sequences using only 0 or 1 where 0 represents the
difference between consecutive beats lower than 5, or 100
msec and 1 the cases in which the difference between two
successive beats exceeded this limit. Then we calculated
all three-digit words that contained either 000 (A) or 111
(B). We call these PN-5-A, PN-100-A and PN-5-B, and
PN-100-B, respectively.
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